IL2RA and myeloid sarcoma: A recent work showed that an IL2ra enhancer, which harbors autoimmunity risk variants and was one of the first MS-associated loci from GWAS, has no impact on the gene level expression, but rather affects gene activation by delaying transcription in response to extracellular stimuli46.